Corcept Therapeutics (NASDAQ:CORT - Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of $0.18 per share for the quarter.
Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its quarterly earnings results on Thursday, February 15th. The biotechnology company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.25 by $0.03. The business had revenue of $135.41 million for the quarter, compared to analysts' expectations of $129.27 million. Corcept Therapeutics had a net margin of 21.86% and a return on equity of 21.98%. The company's quarterly revenue was up 31.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.14 earnings per share. On average, analysts expect Corcept Therapeutics to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Corcept Therapeutics Trading Down 1.2 %
Corcept Therapeutics stock traded down $0.27 during mid-day trading on Thursday, reaching $22.21. The company's stock had a trading volume of 1,176,202 shares, compared to its average volume of 1,473,618. The firm has a market cap of $2.31 billion, a price-to-earnings ratio of 23.74 and a beta of 0.48. Corcept Therapeutics has a twelve month low of $20.84 and a twelve month high of $34.28. The business has a 50 day moving average price of $23.86 and a 200-day moving average price of $25.40.
Analyst Upgrades and Downgrades
CORT has been the subject of a number of recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $38.00 price objective on shares of Corcept Therapeutics in a research report on Tuesday. StockNews.com raised Corcept Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday. Finally, Truist Financial upped their price objective on Corcept Therapeutics from $36.00 to $42.00 and gave the stock a "buy" rating in a research note on Friday, February 16th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $39.30.
View Our Latest Research Report on CORT
Insider Buying and Selling
In other Corcept Therapeutics news, insider Sean Maduck sold 27,068 shares of the firm's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.97, for a total transaction of $702,955.96. Following the transaction, the insider now owns 74,455 shares of the company's stock, valued at approximately $1,933,596.35. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Corcept Therapeutics news, insider Sean Maduck sold 27,068 shares of the company's stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.97, for a total value of $702,955.96. Following the completion of the sale, the insider now directly owns 74,455 shares in the company, valued at $1,933,596.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Joseph Douglas Lyon sold 1,000 shares of Corcept Therapeutics stock in a transaction on Friday, February 16th. The shares were sold at an average price of $26.00, for a total value of $26,000.00. Following the transaction, the chief accounting officer now owns 6,774 shares in the company, valued at $176,124. The disclosure for this sale can be found here. Insiders sold 83,783 shares of company stock valued at $2,118,996 over the last 90 days. 19.80% of the stock is currently owned by company insiders.
About Corcept Therapeutics
(
Get Free Report)
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Further Reading
Before you consider Corcept Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corcept Therapeutics wasn't on the list.
While Corcept Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
